低剂量顺铂节律化疗抗血管生成作用的实验研究
来源:岁月联盟
时间:2015-10-12
总之,低剂量节律化疗抗血管生成作用是近来提出的新观点,其前期临床试验具有可行性优势,但目前仍有许多挑战需要克服以提高临床用药的成功率。随着研究的深入,低剂量节律化疗有望成为晚期肿瘤姑息治疗的一种新选择,通过提高病人的生活质量,使之长期带瘤生存,使那些不易治愈的肿瘤成为可控性疾病。
【参考文献】
[1]FOLKMAN J. Angiogenesis and apoptosis[J]. Semin Cancer Biol, 2003,13(2):159167.
[2]HANAHAN D, BERGERS G, BERGSLAND E. Less is more, regularly:metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice[J]. J Clin Invest, 2000,105(8):10451047.
[3]PICCARTGEBHARTM J. Mathematics and oncology: a match for life[J]? J Clin Oncol, 2003,21(8):14251428.
[4]BERTOLINI F, PAUL S, MANCUSO P, et al. Maximum tolerable dose and lowdose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells[J]. Cancer Res, 2003,63(5):43424346.
[6]周晓彬,纪新强,徐莉. 医用统计学软件PPMS 1.5的组成和应用特点[J]. 齐鲁医学杂志, 2009,24(1):2932.
[6]HAHNFELDT P, FOLKMAN J, HLATKY L. Minimizing longterm tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis[J]. Theor Biol, 2003,220(4): 545554.
[7]MILLER K D, SWEENEY C J, SLEDGE G W. Redefining the target:chemotherapeutics as antiangiogenics[J]. J Clin Oncol, 2001,19(4):11951206.
[8]KLEMENT G, HUANG P, MAYER B, et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an antiVEGFR2 antibody in multidrugresistant human breast cancer xenografts [J]. Clin Cancer Res, 2002,8(1):221232.
[9]NGUYEN M, SHING Y, FOLKMAN J. Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane[J]. Microvasc Res, 1994,47:3140.
[10]MOSMANN T. Rapid colorimetric assay for celluar growth and survival: application to proferation and cytotoxicity assays[J]. J Immunol Methods, 1983,65:5563.
[11]王延涛,沈方臻,侯继院. 低剂量顺铂并IFNα对小鼠移植性肝癌血管生成影响[J]. 青岛大学医学院学报, 2008,44(1):37.
[12]侯继院,沈方臻,王延涛,等. 顺铂低剂量节律化疗抑制小鼠H22肝癌血管生成观察[J]. 齐鲁医学杂志, 2008,23(2):95.
上一篇:脱敏组方抗Ⅰ型变态反应的实验研究
下一篇:围手术期药物过敏反应